Breathing Innovation: Ab Initio Pharma at RDD Europe 2025
Ab Initio Pharma is pleased to announce that our team will be attending Respiratory Drug Delivery (RDD) Europe 2025, taking place at the Estoril Congress Center in Portugal from May 6–9, 2025. Now celebrating its 20th anniversary and co‑organised by RDD Online and Aptar Pharma, this premier conference will bring together around 500 scientists, engineers, clinicians, regulators and business professionals for four days of in‑depth podium sessions, interactive workshops and themed Knowledge Spaces, .
At Ab Initio Pharma, we specialise in end‑to‑end GMP manufacture of inhalation products for clinical trials. Whether you’re developing dry powder inhalers (DPIs), pressurized metered‑dose inhalers (MDIs) or innovative soft‑mist devices, our Australian delivers small‑batch through pilot‑scale production under robust quality systems. We offer formulation development, analytical method support, stability testing, regulatory guidance and release to accelerate your pulmonary drug delivery programs from first‑in‑human studies through later phase trials.
We’d love to connectlook for our team throughout the conference breaks or drop us a note to set up a meeting. Let’s discuss how Ab Initio can help bring your next-generation inhalation therapy to the clinic.
